Log in

NASDAQ:KURAKura Oncology Stock Price, Forecast & News

$8.23
-0.47 (-5.40 %)
(As of 04/8/2020 01:16 AM ET)
Add
Compare
Today's Range
$8.18
Now: $8.23
$9.09
50-Day Range
$6.45
MA: $10.06
$12.60
52-Week Range
$6.35
Now: $8.23
$21.42
Volume384,400 shs
Average Volume346,734 shs
Market Capitalization$373.87 million
P/E RatioN/A
Dividend YieldN/A
Beta2.05
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia. It is also developing KO-947, a small molecule inhibitor of extracellular signal related kinase used for the treatment of patients with tumors that have dysregulated activity due to mutations or other mechanisms in the mitogen-activated protein kinase pathway; and KO-539, a small molecule inhibitor of the menin-mixed lineage leukemia protein-protein interaction. The company was founded in 2014 and is headquartered in San Diego, California.
Read More
Kura Oncology logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.55 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KURA
CUSIPN/A
Phone858-500-8800

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$4.83 per share

Profitability

Net Income$-63,140,000.00

Miscellaneous

Employees43
Market Cap$373.87 million
Next Earnings Date5/5/2020 (Estimated)
OptionableOptionable

Receive KURA News and Ratings via Email

Sign-up to receive the latest news and ratings for KURA and its competitors with MarketBeat's FREE daily newsletter.


Kura Oncology (NASDAQ:KURA) Frequently Asked Questions

How has Kura Oncology's stock been impacted by COVID-19 (Coronavirus)?

Kura Oncology's stock was trading at $9.65 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, KURA stock has decreased by 14.7% and is now trading at $8.23. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Kura Oncology?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kura Oncology in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Kura Oncology.

When is Kura Oncology's next earnings date?

Kura Oncology is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Kura Oncology.

How were Kura Oncology's earnings last quarter?

Kura Oncology Inc (NASDAQ:KURA) posted its quarterly earnings results on Tuesday, February, 25th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.42) by $0.03. View Kura Oncology's earnings history.

What price target have analysts set for KURA?

7 analysts have issued 12 month price objectives for Kura Oncology's shares. Their forecasts range from $22.00 to $30.00. On average, they expect Kura Oncology's stock price to reach $27.29 in the next twelve months. This suggests a possible upside of 231.5% from the stock's current price. View analysts' price targets for Kura Oncology.

Has Kura Oncology been receiving favorable news coverage?

News articles about KURA stock have trended very negative recently, according to InfoTrie Sentiment. The research group identifies negative and positive news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Kura Oncology earned a daily sentiment score of -3.3 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news aboutKura Oncology.

Who are some of Kura Oncology's key competitors?

What other stocks do shareholders of Kura Oncology own?

Who are Kura Oncology's key executives?

Kura Oncology's management team includes the following people:
  • Dr. Troy Edward Wilson, Chairman, CEO & Pres (Age 50)
  • Dr. Antonio Gualberto, Head of Devel. & Chief Medical Officer (Age 54)
  • Dr. Marc Grasso, CFO & Chief Bus. Officer
  • Mr. John Farnam, Chief Operating Officer
  • Mr. Pete De Spain, VP of Investor Relations & Corp. Communications

What is Kura Oncology's stock symbol?

Kura Oncology trades on the NASDAQ under the ticker symbol "KURA."

How do I buy shares of Kura Oncology?

Shares of KURA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Kura Oncology's stock price today?

One share of KURA stock can currently be purchased for approximately $8.23.

How big of a company is Kura Oncology?

Kura Oncology has a market capitalization of $373.87 million. The company earns $-63,140,000.00 in net income (profit) each year or ($1.51) on an earnings per share basis. Kura Oncology employs 43 workers across the globe. View additional information about Kura Oncology.

What is Kura Oncology's official website?

The official website for Kura Oncology is http://www.kuraoncology.com/.

How can I contact Kura Oncology?

Kura Oncology's mailing address is 3033 SCIENCE PARK ROAD SUITE 220, SAN DIEGO CA, 92121. The company can be reached via phone at 858-500-8800 or via email at [email protected]

This page was last updated on 4/8/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel